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E D I T O R I A L
Finnish neuroscience from past to present
1 |  INTRODUCTION
Finland is a small Nordic country (population 5.5  million) 
that enjoys a richness and diversity of research activities in-
cluding those in the neurosciences. In this article, we will 
briefly review the history of neuroscience in Finland from 
its origins such as the studies into the anatomy, pathology 
and physiology of the nervous system—which were recog-
nized with the award of the Nobel Prize in Physiology or 
Medicine—to later discoveries in clinical, molecular and 
translational neurosciences and pharmacology. The innova-
tive original research of Finnish investigators on weak mag-
netic fields in the human brain has led to the development of 
advanced imaging techniques. Another area associated with 
many recent breakthroughs has been human genetics and the 
identification of the molecular genetic causes and risk factors 
of a number of nervous system disorders.
2 |  THE BEGINNINGS OF 
NEUROSCIENCE IN FINLAND  
(CA. 1600–1900)
For more than 600 years, until 1809, Finland was an integral 
part of the Kingdom of Sweden. The Helsinki-born, Sigfridus 
Aronus Forsius (ca. 1560–1624), Professor of Astronomy 
at the University of Uppsala, became Royal Astronomer 
and was one of the most prominent scholars of the Nordic 
renaissance. He was the first Finn, and probably the first 
Nordic researcher, to consider the nervous system at a scien-
tific level. His extensive treatise “Physica” (Forsius, 1952), 
completed in 1611 and largely based on Johannes Magirus 
work “Physiologia Peripatetica” (1597), included a detailed 
account of the structure and function of the central and pe-
ripheral nervous systems and sensory organs. Influenced by 
Paracelsus, he firmly rejected the still-widespread cardiocen-
tric ideas of Aristotle, instead postulating an encephalocen-
tric view.
The formal academic study of medicine began in Finland 
in 1640 with the establishment of the Royal Academy of 
Turku. This was transferred to Helsinki in 1828 and is now 
known as the University of Helsinki. An independent Helsinki 
University of Technology (the present Aalto University) was 
established in 1849. Further multidisciplinary universities 
with faculties of medicine or natural sciences were founded 
in Turku 1918 and 1920, Tampere 1925, Jyväskylä 1934, 
Oulu 1958, and Kuopio 1966 (now the University of Eastern 
Finland).
During its first century of activity, most of the profes-
sors of medicine in the Royal Academy of Turku had earned 
their doctorates at the leading Dutch universities. Although 
their teachers included such men as Sylvius and Boerhaave, 
they did not show any particular interest in neuroscience. 
Even the extensive thesis “De apoplexia” (1771) written by 
Johan Haartman (1725–1787), a pupil of Linnaeus, was a 
mere compilation of current knowledge. The papers of Evert 
J. Bonsdorff (1810–1898) and his disciples on the compar-
ative anatomy of the cranial nerves and the structure of the 
human sympathetic nervous system represent the first truly 
original Finnish contributions to neuroscience. One of his 
students, Otto E. A. Hjelt (1823–1913), who in 1859 was 
appointed as the first Professor of Pathological Anatomy 
in the University of Helsinki, also carried out experimental 
work on the regeneration of peripheral nerves after excision 
in rabbits. This work was proposed and supervised by his 
teacher and life-long friend Rudolf Virchow, the founder of 
cellular pathology and carried out in 1857–1858 partly in 
Virchow´s laboratory in the Charité in Berlin and partly in 
Helsinki.
Hjelt's successor as Professor of Pathological Anatomy 
was E. Alexander Homén (1851–1926) who had spent his 
“postdoc” time in the 1880s with Virchow´s brilliant stu-
dent, Julius Cohnheim, a pioneer of experimental pathology, 
in Leipzig as well as with Louis-Antoine Ranvier and Jean-
Martin Charcot in Paris. Inspired by his prominent teachers, 
Homén (Figure 1) became not only the first Finnish neuropa-
thologist but also the founder of clinical neurology in Finland. 
Even from an international point of view, Homén can be con-
sidered as one of the first experimental neuropathologists. He 
carried out experimental studies on the secondary degenera-
tion of the canine spinal tracts after hemisection of the cord 
and also investigated how cutting the nerve affected the nerve 
cell somas. He later devoted much of his energy to experi-
mental studies on the effects of the newly discovered bacteria 
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and their toxins on the nervous system. Following Virchow's 
model developed in the Charité, Hjelt had a small clinical 
ward in the university teaching hospital attached to his in-
stitute. Homén transformed this clinical ward into the first 
specialized clinical neurological unit in Finland. Although 
Homén published many clinicopathological works, his most 
notable is the series of publications beginning in 1890 which 
contain the original clinical and pathological descriptions of 
hepatolenticular degeneration (also known as Wilson's dis-
ease). Kinnier Wilson, in his much later report on the same 
disease in 1912, not only cited Homén extensively but also 
republished one of Homén´s patient photographs (Haltia & 
Kivalo, 1992).
3 |  DEVELOPMENT OF CLINICAL 
NEUROLOGY, NEUROSURGERY 
AND NEUROPATHOLOGY FROM 
1900
Christian Sibelius (1869–1922), one of Homén´s students 
and the younger brother of the composer Jean Sibelius, car-
ried out pioneering studies of the effects of carbon monox-
ide on the nervous system, and in 1909 was appointed first 
as a personal professor and in 1921 as the first full profes-
sor of neuropsychiatry in the University of Helsinki. Jarl 
Hagelstam, another member of Homén´s team, served as 
personal professor of neurology (Haltia & Kivalo, 1992). 
The first permanent academic chair of clinical neurology in 
Finland was only established in the University of Helsinki 
as late as 1963. Its first holder, Erkki Kivalo (1929–2009), 
was a far-sighted and highly energetic organizer whose work 
contributed to the establishment of academic departments of 
neurology in all five Finnish medical schools in Helsinki, 
Turku, Tampere, Oulu and Kuopio. Aarno Snellman, a stu-
dent of Herbert Olivecrona, became the first personal profes-
sor of neurosurgery in 1947 and Matti Haltia was appointed 
the first professor of neuropathology in 1990, both in the 
University of Helsinki. Over the years, Finnish neurologists, 
neurosurgeons and neuropathologists have been particularly 
fascinated by the inherited, degenerative and vascular disor-
ders of the nervous system.
3.1 | Discovery of neurological 
diseases and their molecular causes
The rather unique population history of Finland with long-
term stable regional subpopulations, the excellent popu-
lation and health registers, and the generally favourable 
attitude towards medical research are all factors explaining 
why Finland is such a good country for investigating genetic 
factors in human diseases. From the 1970s onwards, close 
collaboration between clinical neurologists, clinical geneti-
cists and neuropathologists has led to the discovery and/or 
characterization of a number of previously unrecognized or 
poorly known monogenic disorders of the nervous system 
and musculature.
3.1.1 | Childhood-onset diseases
Early examples of childhood-onset diseases include the 
detailed clinical and biochemical characterization of aspar-
tylglycosaminuria by Seppo Autio, Jorma Palo and their 
collaborators (Palo & Mattsson, 1970). At neuropathologi-
cal examination, aspartylglycosaminuria showed the fea-
tures of a generalized lysosomal storage disorder (Haltia, 
Palo, & Autio, 1975). Another early example is infantile 
neuronal ceroid lipofuscinosis (CLN1), described jointly 
by the child neurologist, Pirkko Santavuori and Matti Haltia 
and their collaborators (Haltia, Rapola, & Santavuori, 1973; 
Haltia, Rapola, Santavuori, & Keranen, 1973; Santavuori, 
Haltia, Rapola, & Raitta, 1973). Additional examples of 
fruitful interactions between paediatric neurologists and 
neuropathologists, particularly Anders Paetau, are listed 
in Table 1. It was the identification and careful clinical 
and pathological characterization of these diseases which 
laid the foundations for the successful elucidation of the 
underlying causative genetic defects. The genes and mu-
tations responsible for almost all of these disorders have 
already been identified, largely by the groups of renowned 
molecular geneticists at the University of Helsinki, Albert 
F I G U R E  1  E. Alexander Homén (1851–1926), the first Finnish 
neuropathologist and the founder of clinical neurology in Finland 
(photo Matti Haltia & Erkki Kivalo)
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de la Chapelle, Leena Peltonen, Anna-Elina Lehesjoki and 
Juha Kere. In the case of aspartylglycosaminuria, a mouse 
model was developed and it was observed that an adeno-
virus-mediated gene transfer resulted in decreased lysoso-
mal storage in the brain, and a total correction in the liver 
(Peltola et al., 1998).
3.1.2 | Adult-onset diseases
New forms of adult-onset monogenic neurological dis-
orders have been identified through collaboration of cli-
nicians, neuropathologists and clinical and molecular 
geneticists. Early examples include hereditary gelsolin 
amyloidosis (Meretoja disease), with cranial and peripheral 
neuropathy (Haltia et al., 1990; Meretoja, 1969) caused by 
mutations in the gelsolin gene (Levy et al., 1990), and a 
presenile frontotemporal dementia with bone lesions called 
polycystic lipomembranous osteodysplasia with scleros-
ing leukoencephalopathy (PLOSL or Nasu-Hakola disease; 
Hakola, 1972; Paloneva et al., 2001). PLOSL is caused by 
mutations in the TYROBP and TREM2 genes which both 
code for components of the same membrane signalling 
complex (Paloneva et al., 2000, 2002). Creutzfeldt-Jakob 
disease, identified in a Finnish family (Haltia, Kovanen, 
Crevel, Bots, & Stefanko, 1979), co-segregated with the 
codon 178Asn PRNP mutation (Goldfarb et al., 1991). 
Strikingly, this dominantly inherited disease was also 
shown to be transmissible (Goldfarb et al., 1992). Two 
Finnish families with phenotypically perplexing forms of 
presenile Alzheimer´s disease proved to be particularly 
interesting. Their challenging molecular genetic analysis 
was performed in collaboration with John Hardy's group. 
The first family, who displayed prominent myoclonus, 
turned out to be linked to chromosome 14 (Haltia et al., 
1994) and they were shown to carry one of the first muta-
tions to be identified in the presenilin-1 gene (Alzheimer's 
Disease Collaborative,  Group, 1995). In contrast, variant 
Alzheimer´s disease with spastic paraparesis and “cotton 
wool plaques” (Crook et al., 1998) was shown to be caused 
by a deletion of exon 9 of the presenilin 1 gene (Prihar 
et al., 1999). One of the latest findings is related to familial 
and sporadic forms of amyotrophic lateral sclerosis (ALS) 
and frontotemporal dementia. About 50% of the Finnish fa-
milial and 20% of the sporadic cases have a hexanucleotide 
repeat expansion in the C9ORF72 gene (Laaksovirta et al., 
2010; Renton et al., 2011). About 30% of all Finnish ALS 
patients have a C9ORF72 or SOD1*D91A gene mutation, 
making Finland well-suited for mutation-based clinical tri-
als. A special type of late onset spinal muscular atrophy 
(Jokela type; Jokela et al., 2011), with slow progression 
(sometimes initially diagnosed as ALS), was identified in 
northern Karelian families and was found to be caused by a 
CHCHD10 mutation (Penttila et al., 2015).
Inherited myopathies first discovered by Finnish investi-
gators include X-linked myopathy with excessive autophagy 
Disease References
Aspartylglycosaminuria (AGU) Palo and Mattsson (1970) and 
Haltia et al. (1975)
Infantile neuronal ceroid lipofuscinosis (CLN1) Haltia, Rapola and Santavuori 
(1973), Haltia, Rapola, Santavuori 
and Keranen (1973) and 
Santavuori et al. (1973)
Late infantile neuronal ceroid lipofuscinosis (CLN5) See Mole and Haltia (2015)
Progressive epilepsy with mental retardation (CLN8) See Mole and Haltia (2015)
Congenital neuronal ceroid lipofuscinosis (CLN10) See Mole and Haltia (2015)
Progressive myoclonus epilepsy (EPN1) Haltia, Kristensson, and Sourander 
(1969) and Koskiniemi, Donner, 
Majuri, Haltia, and Norio (1974)
Progressive encephalopathy with oedema, 
hypsarrhythmia and optic atrophy (PEHO)
Haltia and Somer (1993) and 
Salonen, Somer, Haltia, Lorentz, 
and Norio (1991)
Muscle–eye–brain disease (MEB) Haltia et al. (1997) and Santavuori 
et al. (1998)
Hydrolethalus syndrome Paetau et al. (2008)
Infantile onset spinocerebellar ataxia (IOSCA) Koskinen et al. (1994) and 
Lonnqvist, Paetau, Nikali, 
Boguslawski, and Pihko (1998)
Foetal motoneuron disease Nousiainen et al. (2008)
T A B L E  1  Early-onset neurological 
disorders discovered and/or characterized by 
Finnish investigators
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(Kalimo et al., 1988) and tibial muscular dystrophy (Udd 
et al., 1998). The latter condition is caused by mutations in 
the gene encoding the giant skeletal-muscle protein, titin 
(Hackman et al., 2002).
3.1.3 | Mitochondrial disorders
Important research on mitochondrial abnormalities induc-
ing both neurodegenerative and muscle disorders has been 
carried out by the groups of Anu Suomalainen (Helsinki), 
Howard Jacobs (Tampere) and Kari Majamaa (Oulu). The 
neurologist, Maria Rantamäki (Tampere), reported details of 
a family with autosomal recessive ataxia with thalamic le-
sions (Rantamaki et al., 2001). Similar families were found 
in other European countries, which led to the identification 
of one of the most common inherited ataxia syndromes in 
the Western world, neurodegenerative disorder MIRAS (mi-
tochondrial autosomal recessive ataxia syndrome), caused by 
mutations in the POLG1 gene (Hakonen et al., 2005; Van 
Goethem et al., 2004). Dozens of further genetic defects have 
been discovered in mitochondrial disorders in Finland and, 
importantly, some of these conditions have been subjected to 
animal modelling and translational treatment trials (Nunnari 
& Suomalainen, 2012; Suomalainen & Battersby, 2017).
3.2 | Identification of genetic risk factors of 
common neurological diseases
Soon after the discovery of the APOE e4 allele as a major 
risk factor of Alzheimer's disease (Strittmatter et al., 1993), 
Polvikoski and co-workers (Polvikoski et al., 1995) con-
ducted the first population-based neuropathological study 
of its impact. This demonstrated that APOE e4 is associated 
with increased cortical deposition of amyloid beta protein. 
In another Finnish population-based study, the magnitude 
of the genetic effect of APOE e4 was put into perspective. 
This study investigated a cohort of 980 people aged 69–78 
and observed that even in subjects homozygous for APOE 
e4, about 80% were non-demented (Kuusisto et al., 1994). A 
convincing link was also found between Alzheimer's disease 
and insulin metabolism (Kuusisto et al., 1997), and mid-life 
serum cholesterol levels in two Finnish population-based 
studies (Kivipelto et al., 2001; Notkola et al., 1998). These 
and other epidemiological observations led to a randomized 
controlled trial (the Finnish Geriatric Intervention Study to 
Prevent Cognitive Impairment and Disability, FINGER), 
which demonstrated that a multidomain intervention on 
vascular risk factors helps in the maintenance of cognitive 
functions in elderly people (Ngandu et al., 2015). A more 
recent population-based study showed that 1 in 200 people 
in Eastern Finland carry an APP*A673T variant that confers 
some protection from Alzheimer's disease and that this 
variant associates with decreased amyloid peptide levels in 
plasma (Martiskainen et al., 2017).
Some of the genetic studies investigating common mi-
graine were originally initiated in Finland, but these soon ex-
panded to involve large multinational consortia. These have 
revealed that vascular factors play a predominant role in the 
mechanisms of migraine (Gormley et al., 2016). Exceptional 
familial clustering of multiple sclerosis (MS) was discov-
ered in the western Finnish region of Southern Ostrobothnia 
(Wikstrom, 1975). Genetic studies of families from this re-
gion resulted in the first genetic linkages in MS (Kuokkanen 
et al., 1996; Tienari et al., 1992, 1993). Studies in Parkinson´s 
disease have shown that rare variants of mitochondrial DNA 
polymerase gamma (POLG1) are risk factors in Parkinson´s 
disease in Finland (Eerola et al., 2010; Luoma et al., 2007; 
Ylonen et al., 2017).
3.3 | Cerebrovascular disorders: Pioneering 
new treatments
Helsinki University Hospital, along with Heidelberg 
University Hospital, were the first centres to start thromboly-
sis treatments in acute ischaemic stroke. Two neurologists, 
Markku Kaste and Perttu Lindsberg, played an important 
role not only in setting up these treatments but also in char-
acterizing the molecular events of the thrombotic vascular 
wall (Lindsberg, Carpen, Paetau, Karjalainen-Lindsberg, & 
Kaste, 1996).
The Department of Neurosurgery in the Helsinki 
University Hospital has a long tradition of offering surgical 
treatment of intracerebral aneurysms and became a world 
class centre of cerebrovascular surgery under the leadership 
of Juha Hernesniemi. He and his fellow neurosurgeons, Mika 
Niemelä (Helsinki), Juhana Frösen and Juha Jääskeläinen 
(both in Kuopio now), initiated studies on the histochem-
istry of the ruptured aneurysm wall and established an ex-
perimental model of arterial aneurysms (Frosen et al., 2004; 
Marbacher et al., 2014).
4 |  DISCOVERIES IN 
PSYCHIATRY: FROM PET IMAGING 
TO GENETICS AND TRANSLATION
Many Finnish psychiatrists and neuroscientists have applied 
biological approaches to psychiatric problems. Much of the 
work in this field has been conducted using the positron emis-
sion tomography (PET) technique in the national PET cen-
tre in Turku (neuroscience studies led by Jarmo Hietala and 
Juha Rinne). Among these studies, the report of the contribu-
tion of the A1 allele on dopamine D2 receptor availability 
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has attracted considerable interest (Pohjalainen et al., 1998). 
Other imaging studies using MRI have revealed that there is 
a decreased volume of the posterior hippocampus in subjects 
with psychopathy (Laakso et al., 2001).
Severe impulsivity/aggression leading to suicidal, violent 
and criminal acts was found to be associated with blunted se-
rotonin neurotransmission by Markku Linnoila (1947–1998), 
Mika Scheinin, Matti Virkkunen and collaborators (Linnoila 
et al., 1983), identifying a form of early-onset male alco-
holism with a tendency to impulsive and violent behaviour. 
More recently, it was found that some of the individuals with 
this type of behaviour have an early stop codon that inacti-
vates 5-HT2B receptors in a Finnish population (Bevilacqua 
et al., 2010).
As early as the 1960s, the excellent “Finnish person file 
registers” have been used in designing epidemiological co-
hort studies as well as twin and adoption studies, with the aim 
of clarifying the contributions of genetic and environmental 
factors in the development of schizophrenia (Isohanni et al., 
2001; Tienari et al., 2004). The successful family studies 
initiated by Leena Peltonen and Jouko Lönnqvist (Ekelund 
et al., 2001) have expanded and are now large international 
genome-wide association studies; this was necessary in order 
to include sufficient schizophrenic subjects to allow the iden-
tification of common and rare genetic variants with small 
joint effects on susceptibility (Schizophrenia Working Group 
of the Psychiatric Genomics, 2014). The eventual success 
in psychiatric genetics has stimulated the ongoing SUPER 
study, which will enrol more than ten thousand psychotic 
patients with the goal of analysing genetic risk factors as a 
part of the international Stanley Global Neuropsychiatric 
Genomics Initiative (https ://www.fimm.fi/en/resea rch/grand-
chall enge-progr ammes/ finni sh-genom es-empow ering-perso 
nalis ed-and-predi ctive-healt h/super ). One exciting recent 
development in population-wide psychiatric genomics is the 
large FinnGen project (https ://www.finng en.fi), led by Aarno 
Palotie, which intends to determine how genes affect our dis-
eases and drug responses, including nervous system diseases, 
by combining clinical characteristics with genome-wide 
polymorphisms among different disease categories, using the 
valuable biobank collections from Finnish hospitals and re-
search institutions.
Other important topics in psychiatry have included the 
characterization of suicide victims and the methods to re-
duce suicides and attempted suicides in studies led by Jouko 
Lönnqvist (Henriksson et al., 1993). The increased research 
interest and public attention being devoted to depression and 
attempted suicides have been associated with an approxi-
mately 50% reduction in suicides in Finland from 1990 to 
2015.
Several neuroscientists in Finland have started transla-
tional studies in psychiatry. The group of Eero Castrén has 
increased our understanding of how antidepressants modify 
brain plasticity (Castren & Kojima, 2017; Sairanen, Lucas, 
Ernfors, Castren, & Castren, 2005). There has also been a 
major focus on gene polymorphisms identified in both ani-
mal models and human patients, one example being research 
on anxiety disorders and the mouse models devised by Iiris 
Hovatta and her group (Hovatta et al., 2005). Heikki Rauvala's 
group has cloned and conducted pioneering work on the 
AMIGO-Kv2.1 potassium channel complex (Kuja-Panula, 
Kiiltomaki, Yamashiro, Rouhiainen, & Rauvala, 2003). They 
found schizophrenia-like behavioural and pharmacological 
abnormalities in AMIGO knock-out mice. Based on these 
findings and in collaboration with the psychiatrist, Tiina 
Paunio, AMIGO loss-of-function variants were discovered as 
risk factors of schizophrenia (Peltola et al., 2016).
5 |  ADVANCES IN 
TRANSLATIONAL NEUROLOGY
Neurotrophic factors are important regulators of neural de-
velopment and differentiation acting via specific membrane-
bound receptors which influence gene expression. These 
molecules have also raised high hopes that it may be possible 
to develop effective therapies for various neurodegenerative 
diseases. One family of neurotrophic factors, the neurotro-
phins, has been the focus of interest of Finnish scientists 
working on nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF; Castren, Zafra, Thoenen, & 
Lindholm, 1992; Lindholm, Heumann, Meyer, & Thoenen, 
1987; Zafra, Castren, Thoenen, & Lindholm, 1991) in the 
laboratory of Hans Thoenen in the Max Planck Institute for 
Psychiatry in Munich. The work on BDNF in neuronal plas-
ticity has continued in Helsinki in the group of Eero Castrén 
(Karpova et al., 2011; Maya Vetencourt et al., 2008), whilst 
Dan Lindholm has studied neuronal apoptosis (Hyrskyluoto 
et al., 2013) and novel functions for NGF and its precur-
sor, pro-NGF in lipid signalling (Pham et al., 2019). Glial 
cell-derived neurotrophic factor (GDNF) is another trophic 
factor that promotes the survival of cultured mesencephalic 
dopaminergic neurons which are known to degenerate in 
Parkinson's disease. In another laboratory in Helsinki, Mart 
Saarma has studied the function of GDNF and its receptors 
in the brain and other tissues (Airaksinen & Saarma, 2002). 
In addition, the Saarma group (University of Helsinki) has 
cloned a newly discovered trophic factor, named “cerebral 
dopamine neurotrophic factor” (CDNF), an endoplasmic 
reticulum-associated molecule which possesses neuropro-
tective and neurorestorative properties in rodent and pri-
mate models of Parkinson's disease (Garea-Rodriguez et al., 
2016; Lindahl, Saarma, & Lindholm, 2017; Lindholm et al., 
2007). The first clinical trials with CDNF in Parkinson's dis-
ease patients are currently ongoing, launched by the Finnish 
Company, Herantis Pharma.
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Along with trophic factors, different stem cells may 
have been shown to have some potential in the treatment of 
Parkinson's disease and other neurodegenerative disorders. 
The technology of induced pluripotent stem cells (iPSCs) 
in neuroscience has been advocated in Finland by Jari 
Koistinaho and some other investigators (Holmqvist et al., 
2016; Oksanen et al., 2017).
Epileptic seizures with rewiring of neuronal connections 
can be a consequence of ischaemic and traumatic brain in-
juries. In Kuopio, Asla Pitkänen has delved into the mo-
lecular mechanisms and gene alterations in post-ischaemic 
brain in order to understand the process of epileptogenesis 
(Pitkanen, Ekolle Ndode-Ekane, Lapinlampi, & Puhakka, 
2018). Epilepsy is also associated with mutations in specific 
genes controlling neuronal development and excitation, al-
tering the balance between the excitatory glutamate and the 
inhibitory GABAergic systems. Several genes linked to epi-
lepsy and encephalopathy have been described by the group 
of Anna-Elina Lehesjoki (Anttonen et al., 2017; Virtaneva 
et al., 1997).
6 |  SIGNIFICANT DISCOVERIES 
IN NEUROPHYSIOLOGY
Homén´s colleague, Robert Tigerstedt (1853–1923), 
Professor of Physiology in the University of Helsinki (1900–
1919) and a world authority in circulatory physiology, also 
initiated a tradition of neurophysiology in Helsinki.
Ragnar Granit (1900–1991, Figure 2), a postdoctoral student 
of Charles Scott Sherrington and Professor of Physiology in 
the University of Helsinki in 1935–1940, carried this research 
tradition further by investigating the physiology of vision. He 
received the Nobel Prize in Physiology or Medicine in 1967 to-
gether with Keffer Hartline and George Wald for their discov-
eries concerning the primary physiological and chemical visual 
processes in the eye, identifying different types of cones in the 
retina representing three characteristic spectral sensitivities. 
Granit started his medical studies in the University of Helsinki 
in 1919, and while he was interested in the art of painting, he 
became familiar with the psychologist and philosopher, Eino 
Kaila, and the discipline of experimental psychology. After 
revealing the dependence of colour perception on lighting and 
context in his doctoral thesis, Granit became convinced that 
any progress in understanding colour vision would need neuro-
physiological analyses based on electrophysiology. Following 
the pioneering neuroanatomical studies of Santiago Ramón y 
Cajal, the retina seemed to represent a particularly interesting 
research target, especially in the first stages of vision. During 
his postdoctoral period in Oxford in 1928 and 1932–1933, he 
perfected the measurement of the electroretinogram (ERG). His 
major achievement was to analyse the vertebrate ERG response 
as a sum of three separable components. Thereafter in Helsinki, 
he founded the ERG laboratory in the Department of Physiology 
and published important basic information on the functions of 
the retina. He appreciated there was a need to obtain more de-
tailed data of the action potentials of individual neurons. In the 
same department, Alwar Wilska (1911–1987) was developing 
the production of sharp glass–metal electrodes for single neuron 
recordings, work in which Granit's student, Gunnar Svaetichin, 
participated and made further refinements. In 1939, Granit and 
Svaetichin used the microelectrodes to record the activity peaks 
of frog retinal ganglion cells following stimulation with light at 
specific wavelengths, especially the responses to blue, green and 
red light. Their article published in 1939 “Principles and tech-
nique of the electrophysiological analysis of colour perception 
with the aid of microelectrodes” (Granit & Svaetichin, 1939) 
formed the foundation for a large research programme that was 
realized in the early 1940s in the Karolinska Institute, Stockholm, 
to which Granit had been invited after the Winter War between 
Finland and the Soviet Union. His results on multiple species led 
Granit to formulate his so-called modulator–dominator theory 
of colour vision, which, however, has not stood up to the test of 
time. Nonetheless, Granit was the first scientist to demonstrate 
experimentally that colour information could be extracted from 
population responses of neuron types with different spectral 
sensitivities. The characteristics of rods and cones were then 
unknown, but Granit stressed the fact that the brain receives 
the information only via the coded responses from the retinal 
ganglion neurons. Granit's book, “Sensory Mechanisms of the 
Retina” (Granit, 1947), became well-known around the world. 
His work has had lasting effects on Finnish neuroscience.
F I G U R E  2  Ragnar Granit (1900–1991) in his Stockholm study 
in May 1990 (photo Andreo Larsen)
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Kai Otto Donner (1922–1995) undertook his doctoral studies 
in Granit's laboratory and brought visual neuroscience back to 
Helsinki. Active representatives of this line of research include 
Veijo Virsu (1941–2018), Tom Reuter and Kristian Donner and 
their students (Aho, Donner, Hyden, Larsen, & Reuter, 1988; 
Govardovskii, Fyhrquist, Reuter, Kuzmin, & Donner, 2000; 
Koskelainen, Ala-Laurila, Fyhrquist, & Donner, 2000; Rovamo 
& Virsu, 1979; Virsu & Rovamo, 1979). Another Finnish PhD 
student of Granit, Christina Enroth-Cugell (1919–2016) took 
these ideas to the USA.
Towards the end of 1940s, Granit shifted his scientific 
interest to the regulation of muscular movements. This sec-
ond significant research programme of Granit has been con-
sidered to have equal standing to his work on the retina, but 
it has not stimulated the same kind of research tradition in 
Finland as his vision research.
Juhani Hyvärinen (1937–1983, Figure 3) was a Finnish neu-
rophysiologist who received his postdoctoral training in the lab-
oratory of Vernon B. Mountcastle at Johns Hopkins University, 
where he learned to study single neurons in conscious primates, 
a method that made it possible to explore neuronal mechanisms 
of higher cortical functions, such as cognition, learning and 
memory. Supported by funding from the USA, Hyvärinen was 
one of the first European neuroscientists to exploit this valu-
able technique. In his primate laboratory in Helsinki, Hyvärinen 
made several pioneering findings such as describing the func-
tion of neurons in the parietal association cortex (Hyvarinen 
& Poranen, 1974). He demonstrated that attention modulates 
the responses of neurons in the primary somatosensory cor-
tex (Hyvarinen, Poranen, & Jokinen, 1980), and showed that 
early visual deprivation triggers cortical plasticity, as a result 
of which somatosensory inputs to the visual associative cortex 
become enhanced (Hyvarinen, Carlson & Hyvarinen, 1981).
6.1 | Intracellular electrophysiology
There was no work carried out in Finland on intracellular 
electrophysiology until the mid-1970s. All the outstand-
ing experiments done by Granit and others described above 
were based on extracellular recordings of unit spikes or on 
local field potentials generated by neuronal populations. This 
situation changed in 1974, when Kai Kaila (University of 
Helsinki), working as an autodidact undergraduate student 
with no funding in the Department of Zoology, re-invented 
the method of optimizing sharp microelectrodes, and con-
structed “Field Effect Transistor”-based differential ampli-
fiers to record resting membrane potentials as well as action 
potentials in crayfish giant axons. Later, the pioneering work 
by Kaila and co-workers on the biophysical and ionic basis 
of GABAergic transmission led to a substantial revision and 
elaboration of the concept of classical postsynaptic inhibi-
tion proposed by Sir John C. Eccles, who subsequently re-
ceived the Nobel Prize in 1963. In a seminal article (Kaila & 
Voipio, 1987), Kaila and Voipio showed that, in addition to 
Cl−, bicarbonate ions (HCO−
3
) were responsible for a major 
depolarizing component of the current mediated by GABAA 
receptors. This finding resolved what had seemed “paradoxi-
cal” observations of depolarizing GABA actions in mature 
cortical neurons, which are now considered to play a role in 
seizures and epilepsy. Later, Kaila and co-workers published 
another important article (Rivera et al., 1999), where they 
identified the K+-Cl− cotransporter KCC2 as the major ion 
pump that is not only essential for hyperpolarizing “Eccles-
type” inhibitory currents, but also underlies the presently 
well-known developmental shift from the depolarizing to hy-
perpolarizing actions of GABA which occur during neuronal 
maturation. Apart from the ontogeny of GABAergic signal-
ling, KCC2 and related transporters are now also recognized 
as key molecules in the field of neuronal plasticity and trauma, 
as well as in psychiatric disorders, epilepsy, chronic pain and 
many other CNS diseases (Kaila, Price, Payne, Puskarjov, & 
Voipio, 2014).
7 |  LOW TEMPERATURE 
PHYSICS, WEAK 
MAGNETIC FIELDS AND 
MAGNETOENCEPHALOGRAPHY
The physicist, Olli V. Lounasmaa (1930–2002), founded 
the Low Temperature Laboratory in 1965 at the Helsinki 
University of Technology in Otaniemi, Espoo, the present 
Aalto University. His laboratory became world famous in 
F I G U R E  3  Juhani Hyvärinen (1937–1983; photo Lea 
Hyvärinen)
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achieving records in low temperatures, based on their research 
into superfluid helium-3 and nuclear magnetism. Research on 
brain mechanisms was started in 1980 using innovative super-
conducting quantum interference devices capable of detecting 
the weak magnetic fields produced by the human brain (Hari 
& Lounasmaa, 1989). These innovations were patented, and in 
1989, five researchers from the laboratory founded a company 
to promote the commercialization and further development of 
the magnetoencephalograph (MEG). This new technology has 
continued to generate innovative research as well as expanding 
the researcher community. Lounasmaa's long-term collabora-
tor, clinical neurophysiologist Riitta Hari, created and has led 
the brain research unit of the laboratory since 1982 onwards. 
She undertook the first single-channel MEG recordings of audi-
tory cortex activity as early as 1978 with Prof. Toivo E. Katila's 
research team working in a small wooden sauna in the forest 
near the Otaniemi campus. Hari's solid background in both 
basic and clinical neurophysiology helped her research team to 
apply MEG to crucial questions, including the neural sources 
of different sensory-evoked responses and brain oscillations, 
cortical motor control, multisensory perception, cognition and 
social interactions (Hari, 2017).
This line of research is still very active. Risto Ilmoniemi 
founded the company Nexstim to commercialize transcranial 
magnetic stimulation technology. In 2018, they were awarded 
the first Finnish-led European Research Council Synergy 
grant for the ConnectToBrain project to develop a clinical 
application of a novel technique, called multi-locus transcra-
nial magnetic stimulation.
7.1 | Neural computation
In the field of neural computation, the mathematician 
Teuvo Kohonen, who worked in the Helsinki University of 
Technology (the present Aalto University), has pioneered 
fundamental theories of associative memory and mapping, 
and developed concepts of self-organized neural maps and 
neural networks (“Kohonen maps”; Kohonen, 1982, 1990).
8 |  COGNITIVE BRAIN 
RESEARCH AND MISMATCH 
NEGATIVITY
The brain is able to differentiate deviant stimuli when these are 
present in a series of repeated stimuli; this is thought to be a 
correlate of how the brain processes memories. Two Finnish 
psychologists, Risto Näätänen and Sirkka Mäntysalo, under-
took seminal interpretations of the EEG recordings performed 
by Mäntysalo in the Institute for Perception TNO (National 
Defence Organisation), the Netherlands. They identified a nega-
tive component of sound-related potentials (Naatanen, Gaillard, 
& Mantysalo, 1978), which they termed mismatch negativity 
(MMN). MMN was elicited by presenting deviant-pitch tones 
among repetitive standard-pitch tones both when the subject lis-
tened actively to the tone stream and when it was ignored that is 
asking the listeners to focus on another tone stream. Therefore, 
MMN was regarded as reflecting automatic (pre-attentive) sen-
sory processing, unlike for example, P300 (or P3b), another 
widely studied event-related potential. This interpretation has 
been supported by numerous subsequent studies (for a review, 
see Naatanen, Paavilainen, Rinne, & Alho, 2007). The MMN 
response has proved to be an important tool in perception and 
attention research and in many cognition-related experiments 
and studies of brain diseases and states. MMN is currently 
being studied as a biomarker in many brain disorders, includ-
ing developmental linguistic disorders, psychoses, and alcohol 
and substance use disorders (Naatanen et al., 2011). MMN is 
evoked by almost any kind of change in a repetitive sound and 
higher-order irregularities and is therefore postulated to indi-
cate automatic auditory intelligence (Naatanen, Astikainen, 
Ruusuvirta, & Huotilainen, 2010) and predictive coding in au-
ditory perception (Denham & Winkler, 2017).
9 |  PIONEERING ADVANCES 
IN CHEMICAL NEUROANATOMY: 
IMAGING CATECHOLAMINES
Olavi Eränkö (1924–1984, Figure 4) studied medicine in 
the University of Helsinki, and was particularly interested in 
physiology, the discipline of his first publication in 1940s. His 
fundamental studies on the fluorescence of formaldehyde-
fixed adrenal gland led to the discovery of formaldehyde-
induced fluorescence of catecholamines (Eranko, 1957). His 
F I G U R E  4  Olavi Eränkö (1924–1984) in his laboratory (photo 
Department of Anatomy, University of Helsinki)
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further development of the method, involving freeze-drying of 
tissues (Eranko, 1954) and the treatment with formaldehyde 
vapour, paved the way to detailed analyses of the aminergic 
neuron systems in the brain (Eranko, 1967), subsequently per-
fected by several Swedish scientists in the groups of Nils-Åke 
Hillarp and Bengt Falck (Carlsson, Falck, Hillarp, Thieme, & 
Torp, 1961; Falck, Thieme, Hillarp, & Torp, 1962).
Eränkö immediately recognized the importance of the 
catecholamine fluorescence of adrenal chromaffin cells 
(Eranko, 1955b), and joined the groups of Marthe Vogt and 
Sir John Gaddum in Edinburgh to apply his analytical meth-
ods to identifying catecholamines. His most widely cited 
papers include one demonstrating the localization of adren-
aline and noradrenaline in the adrenal medulla, published in 
1955 in Nature (Eranko, 1955a), and another describing the 
existence of small intensely fluorescent (SIF) cells in the 
sympathetic ganglia in 1965 (Eranko & Harkonen, 1965). 
The latter cells became one of the main targets of Eränkö’s 
research for the rest of his life. All his research was charac-
terized by high scientific rigour. He was a master of meth-
ods and method development, including quantitation and 
statistics. In addition to scientific papers, in 1955 he pub-
lished a popular handbook “Quantitative methods in histol-
ogy and microscopic histochemistry.” His deep and broad 
knowledge was always available to all of the young scien-
tists in his department, while serving as the professor and 
chairman of the Department of Anatomy of the University 
of Helsinki 1956–1984. In 1984, he was the President 
of the VII International Congress of Histochemistry and 
Cytochemistry held in Helsinki. He passed away only a few 
months after the congress.
10 |  ACHIEVEMENTS IN 
NEUROCHEMISTRY AND 
NEUROPSYCHOPHARMACOLOGY
Neurochemistry was one of the neuroscience disciplines to 
expand in Finland in the 1960s. Sakari Piha and Simo S. 
Oja developed analyzers for amino acids and studied the dy-
namics of these compounds during brain development. Oja 
also later focused on the roles of brain-enriched sulphur-
amino acids cysteine and glutathione and especially taurine 
(Saransaari & Oja, 2000).
Several highlights of Finnish brain research have 
emerged from neuropsychopharmacological laboratories. 
One very interesting line of study was established by Matti 
K. Paasonen and Jouko Tuomisto; they examined the effects 
of psychotropic drugs on brain synapses and on serotonin 
in a model exploiting blood platelets (Paasonen, 1968; 
Paasonen & Vogt, 1956; Tuomisto & Tukiainen, 1976).
Many rather unique experimental studies on the biolog-
ical basis of alcohol addiction were started in the 1950s by 
Olof Forsander and Kalervo Eriksson in the laboratories of 
Alko Inc., the Finnish State Alcohol Company. Their ex-
periments were based on selective breeding of rat lines with 
genetic differences in alcohol preference and alcohol avoid-
ance, (Eriksson, 1968), reviewed in Sommer, Hyytia, and 
Kiianmaa (2006) as well as for high and low alcohol sen-
sitivity, (Eriksson & Rusi, 1981), reviewed in Korpi et al. 
(2015). The roles of brain biogenic amines on alcohol-related 
behaviours were later studied by Liisa Ahtee and Kalervo 
Kiianmaa, among others. Alcohol preference was associ-
ated with a clear predilection for opioid-containing solutions 
and with strong hyperactivity after opioid administration. 
Furthermore, administration of opioid antagonists was able 
to reduce alcohol drinking in these rats, in a manner resem-
bling extinction (Sinclair, 2001). This observation paved the 
way to the current clinical use of two opioid receptor antag-
onists, naltrexone and nalmefene, in the treatment of alcohol 
abuse disorders (Mann, Bladstrom, Torup, Gual, & Brink, 
2013). Alcohol-sensitive rats were also highly sensitive to 
benzodiazepine agonists, such as diazepam. This trait could 
be traced to a single point mutation of the cerebellum-en-
riched GABAA receptor subunit, making the receptor ab-
normally sensitive to benzodiazepines (Hellevuo, Kiianmaa, 
& Korpi, 1989; Korpi, Kleingoor, Kettenmann, & Seeburg, 
1993; Uusi-Oukari & Korpi, 1990). Unfortunately, clear clin-
ical benefits have still to emerge from this discovery.
Pertti Panula has pioneered in elucidating the histami-
nergic system in the brains of rats, zebrafish and humans 
(Panula, Airaksinen, Pirvola, & Kotilainen, 1990; Panula, 
Pirvola, Auvinen, & Airaksinen, 1989; Panula, Yang, & 
Costa, 1984; Sundvik & Panula, 2012). His group and col-
laborators have shown the significance of histamine receptors 
in various brain diseases, such as Parkinson's disease and al-
cohol-related behaviours (Haas & Panula, 2003).
Parkinson's disease has been an important topic for Finnish 
neuroscientists and a successful indication for the largest 
Finnish pharmaceutical company, Orion Pharma. It success-
fully developed a peripheral catechol-O-methyltransferase 
(COMT) inhibitor, entacapone, that is used in combination 
with levodopa and the peripheral decarboxylase inhibitor 
carbidopa to enhance the levels of levodopa reaching the 
brain (Mannisto & Kaakkola, 1999). The company scientists, 
led by Ismo Ulmanen, were able to clone the COMT gene 
(Salminen et al., 1990). The whole project was led by the 
neuropharmacologist, Pekka T. Männistö and the scientific 
director of Orion, Ariel Gordin. Important contributions to 
the success of this work can be traced to the neurologists 
Heikki Teräväinen and Seppo Kaakkola (Helsinki University 
Hospital) and Urpo Rinne (Turku University Hospital), 
who undertook treatment trials with patients. Subsequently, 
Urpo Rinne and Reijo Marttila (University of Turku) have 
been active in imaging, epidemiology and clinical trials of 
Parkinson's disease.
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Another successful drug development project was started by 
the Finnish pharmaceutical company, Farmos Inc., and continued 
by Orion Pharma. This was focused on α-adrenoceptor-acting 
sedatives and analgesics, detomidine, medetomidine and dexme-
detomidine. These drugs are now used as veterinary sedatives. 
Since these drugs selectively activate α2-adrenoceptors (Virtanen, 
Savola, Saano, & Nyman, 1988), their effects can be rapidly re-
versed by injection of the α2-antagonist, atipamezole (Haapalinna 
et al., 1997). More recently, dexmedetomidine has entered inten-
sive care units since it has the ability to evoke light-to-moderate 
sedation without causing respiratory depression (Kallio et al., 
1989). Its mild effect on consciousness has been used to trace the 
brain regions activated during the return of consciousness. The 
results have revealed the important roles of activation of the brain-
stem, thalamus, anterior cingulate cortical arousal networks as 
well as restored functional connectivity within the frontoparietal 
network for the restoration of consciousness (Langsjo et al., 2012).
Repurposing of drugs already in clinical use is an approach 
that is presently used for many indications which have remained 
without satisfactory treatment. One good example is based on 
the findings of Jari Koistinaho and his group in the University 
of Eastern Finland, who found that an old, lipid-soluble 
broad-spectrum antibiotic, minocycline, was not only neuro-
protective but also able to inhibit microglial activation (Tikka, 
Fiebich, Goldsteins, Keinanen, & Koistinaho, 2001). These ef-
fects are independent of its anti-microbial properties. This drug 
is now being widely tested in trials for various neurological and 
neuropsychiatric diseases.
One interesting observation emerging from the field 
of sleep research is that there is an increase in the basal 
forebrain adenosine content during wakefulness which 
rapidly declines during recovery sleep (Porkka-Heiskanen 
et al., 1997). This finding fits well with the fact that Finns 
hold the world record for consuming the highest amount 
of coffee per capita, and of course, coffee contains large 
amounts of the adenosine receptor antagonist, caffeine 
(https ://www.teleg raph.co.uk/trave l/maps-and-graph ics/
count ries-that-drink-the-most-coffe e/). Another important 
finding was the discovery of the connection between the 
appearance of childhood narcolepsy with cataplexy after 
vaccination with adjuvant-containing H1N1-influenza vac-
cine during 2010–11 (Nohynek et al., 2012). This finding 
reinforced the concept that narcolepsy–cataplexy is an au-
toimmune disease (Partinen et al., 2014).
11 |  BRAIN RESEARCH SOCIETY 
OF FINLAND, NORDIC MEETINGS 
AND FINNISH NEUROSCIENCE 
GRADUATE SCHOOLS
The Brain Research Society of Finland (BRSF, https ://www.
brsf.org) was founded in 1973 by Olavi Eränkö, and the society 
promptly joined the International Brain Research Organization 
(IBRO). The first meeting of BRSF in the same year was de-
voted to “Memory.” BRSF joined the Federation of European 
Neuroscience Societies (FENS) in 1998 following the first Forum 
in Berlin, when FENS was established as a successor to the former 
European Neuroscience Association (ENA). BRSF board mem-
bers include basic scientists and clinicians, ensuring that the ex-
panding fields of neuroscience are widely represented. Currently, 
BRSF has over 280 members and it organizes meetings includ-
ing the Neuroscience Finland meeting, Brain Awareness Week 
public symposia, and joint meetings with other scientific socie-
ties. BRSF promotes neuroscience in Finland also by awarding 
the “distinguished neuroscientist of the year” and the “best PhD 
thesis in neuroscience” prizes. Representatives of BRSF have ac-
tively taken part in scientific activities of FENS, in different com-
mittees and in the FENS-Kavli Network of Excellence, as well as 
in training schools, and in the work of FENS Governing Council.
Brain Research Society of Finland is actively engaged in 
promoting neuroscience especially in the Nordic countries. The 
Finnish neurochemist, Simo S. Oja, organized the first Nordic 
Neurochemistry meeting in 1976 in Tampere; this was followed 
by a series of meetings in most Nordic countries. Importantly, 
these Nordic meetings were recently revived with the first 
Nordic Neuroscience meeting held in Trondheim, Norway, in 
2015, the second in Stockholm, Sweden, 2017, with the third in 
Helsinki in 2019 (https ://www.helsi nki.fi/en/confe rence s/3rd-
nordic-neuro scien ce-meeti ng-2019).
11.1 | History of doctoral training in 
neuroscience in Finland
The Finnish Graduate School (GS) system was launched by 
the Ministry of Education in 1995, largely in response to 
the lack of structure and cross-compatibility in the differ-
ent universities and the insufficient amount of teaching (lec-
tures, courses) at the post-graduate level. This GS system 
resulted in the founding of a large number of professional 
and well-coordinated doctoral training programmes. The 
GSs were funded by the Ministry of Education and Culture, 
the Academy of Finland and the respective universities until 
2012, when the reform of national doctoral training ended 
the earmarked funding for doctoral programmes, and the uni-
versities devised their individual doctoral training systems.
The first Finnish doctoral programme in neuroscience 
was founded by Kai Kaila (University of Helsinki) together 
with Riitta Hari (Helsinki University of Technology/Aalto 
University) in 1995. In 1998, the Helsinki Graduate School 
of Neurobiology was expanded to the nationwide level as 
the Finnish Graduate School of Neuroscience (FGSN). The 
FGSN was a joint programme involving the Universities of 
Helsinki, Aalto (Helsinki University of Technology until 
2009), Eastern Finland (University of Kuopio until 2009), 
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Oulu, Turku, and Åbo Akademi. Research groups in these 
universities worked in collaboration to develop doctoral 
training at a national level in neuroscience. Unfortunately, 
the national collaboration in doctoral education was again re-
organized, and the successor of the FGSN, Doctoral Program 
Brain & Mind (B&M) started in January 2012 as a joint doc-
toral programme only involving the University of Helsinki 
and the Aalto University.
These and further developments have led to formalized 
doctoral training that is equally accessible to all students. 
After graduation, they have been employed by academic in-
stitutes, biotechnology and pharmaceutical companies, hos-
pitals and various government offices, and many of them 
now constitute the next generation of principal investigators 
in Finnish neuroscience.
12 |  EFFORTS AIMING TO 
PROMOTE THE INTERACTION 
OF BASIC AND CLINICAL 
NEUROSCIENCES
In 2017, the government of Finland decided to allocate fund-
ing to establish the “Neurocenter Finland”-network as a part 
of the national health strategy (https ://neuro cente rfinl and.fi/
en/). Its goal is to establish a coordinating unit to facilitate 
interactions between all sectors of neuroscience (universities, 
hospitals, industry, patient organizations, government). The 
network is coordinated by the University of Eastern Finland.
13 |  CONCLUSION
The first scientific description by a Finnish scholar of the 
structure and function of the central and peripheral nervous 
systems as well as the sensory organs dates back to 1611 
AD. However, active original research in neuroanatomy 
and neuropathology began in Finland first by the middle 
of the 19th century by Finnish students of Anders Retzius, 
Rudolf Virchow, Louis-Antoine Ranvier and Jean-Martin 
Charcot. During the first half of the 20th century, Finnish 
research in neurophysiology reached a high level and was 
recognized with the award of the Nobel Prize in Physiology 
or Medicine.  More recently, Finnish neuroscience has rap-
idly advanced in multiple areas. This has partly reflected 
the expansion of the Finnish university system, although the 
Helsinki metropolitan area still remains the hub of research 
activity. Apart from pure scientific curiosity, the key to suc-
cess and the main driving force of Finnish neuroscientists has 
been the development of new innovative methods of investi-
gation. They have also been able to profit from the particular 
genetic constitution of the Finnish population and the excel-
lent population and health registers.
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